If a supplied lot fails agreed specifications, we’ll replace it at no cost or refund its purchase price in full.
Quality test failed? Free replacement or full refund.
Off-spec? Free replacement or full refund.
FDA PCAC reviews 7 peptides for the 503A bulks list (BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon). Read our compounder's decision tree. Read our briefing →
FDA PCAC reviews 7 peptides for the 503A bulks list in July. Read →
FDA PCAC: 7 peptides under review. Read →
Long-Arg3 IGF-1 (long-acting IGF-1 analog)
Batch documentation
Ask sales for the IGF-1 LR3 COA matched to the offered batch. Review the recorded tests, specifications, and results against your QA and destination-market requirements before quotation.
Overview
IGF-1 LR3, full name Long R3 IGF-1, is an 83-residue engineered analogue of native IGF-1 built around two specific structural modifications. The first is a 13-residue N-terminal extension that originated serendipitously from an E. coli fusion-protein construct and turned out to dramatically reduce binding affinity for the IGF-binding-protein (IGFBP) family. The second is a single Arg substitution at position 3 (replacing the native Glu3) that further suppresses IGFBP interaction. Together, the two modifications yield a circulating analogue largely freed from IGFBP sequestration. Two practical pharmacology consequences follow: roughly threefold higher biological potency than native IGF-1 in cell-proliferation assays at matched molar concentrations, and an extended functional half-life, since the molecule escapes IGFBP-mediated clearance from circulation. For research-lab buyers, IGF-1 LR3 is offered as a lyophilised powder with a ≥99.0% main-peak HPLC specification. Ask sales for the matching batch COA. SDS-PAGE, bioassay, LAL endotoxin, or other recombinant-protein analytics must be confirmed in the written scope before quotation; no expanded panel is implied by the catalogue summary. Two nominal strengths, 0.1 mg and 1 mg, span bench-scale research workflows.
Applications & buyer fit
GH-axis peptides ship to two main buyer types: compounding pharmacies dispensing under physician supervision, and research labs studying somatotropic-axis pharmacology. Pharmacies typically want sterile-filled vials with the full release packet (sterility, endotoxin, CCI); labs typically want loose-format lyophilized powder with sequence verification. Blends (the CJC-1295 / Ipamorelin combination is the canonical example) are usually co-lyophilized rather than solution-mixed for potency stability.
Sourced for
Buyer fit
Documentation that ships
Procurement note: For sterile-filled vials, confirm whether sterility, endotoxin, and CCI are included in the agreed release packet. For loose lyophilized powder, request the batch COA and separately scope any sequence-level evidence required by the buyer's written procedure.
Primary buyer fit: academic and contract research laboratories.
Specifications
Nasal spray listing · US inventory
IGF-1 LR3 is also listed in this catalog as a nasal spray solution.

Batch COAs and test reports
Each picture is a low-resolution preview of a report's first page, with batch and report numbers covered. For the full, clear report, ask our sales team, naming the product and strength.
Batch COAIGF-1 LR3 1 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Independent test fails? Full refund. How it works
Browse all COAs and reportsRegulatory note
Sold as a pharmaceutical-grade active for research and for compounding-pharmacy formulation where local regulations permit (notably 503A / 503B in the United States and analogous regimes elsewhere). Not a finished dosage form. Sterile-filled vials are available with full release documentation; the buyer is responsible for verifying scheduling and dispense requirements in the destination market.
Selected literature
Frequently asked questions
IGFBP sequestration is the practical obstacle with native IGF-1. In serum and cell-culture environments, less than 1% of total native IGF-1 is free at any given time, the rest is bound to the IGFBP family. That makes dose-response work and concentration-controlled experiments difficult because the effective free concentration cannot be reliably predicted from the nominal added concentration. IGF-1 LR3's two engineered modifications (N-terminal extension plus Arg3 substitution) dramatically reduce IGFBP binding, producing a more linear and predictable dose-response curve. The practical readout in cell-proliferation work is roughly threefold higher potency relative to native IGF-1 at equivalent molar input, with substantially tighter inter-experiment variability as a bonus.
At 83 residues, IGF-1 LR3 sits at the boundary between large peptide and small protein, and in practical terms it is produced by recombinant expression in E. coli rather than by solid-phase synthesis. The analytical approach diverges accordingly from a typical synthetic peptide release: the batch COA reports RP-HPLC chemical purity and mass spec identity (intact-mass or peptide-mapping where appropriate), while SDS-PAGE size confirmation and a cell-proliferation bioactivity assay are available on request, because recombinant material's biological activity can vary with folding even when chemical purity is high. LAL endotoxin per USP <85> is essential rather than optional, the E. coli expression system requires disciplined endotoxin clearance throughout purification, and the released-batch COA documents the result on the applicable batch COA when part of the agreed analytical scope.
Reconstitute in 0.6% acetic acid rather than plain water. The mild acidification keeps the protein in monomer form and avoids the aggregation that can occur at neutral pH on dilute reconstitution. Dilute working stocks should then be prepared in cell-culture-grade BSA-containing buffer (0.1% BSA is typical) to prevent adsorption to glass and plastic surfaces at low working concentrations, this is the load-bearing step for cell-culture work at sub-100 ng/mL, where surface adsorption can otherwise silently halve the effective dose. Sub-divide into single-use aliquots and hold at -20 C. The lyophilised product itself rolls under the standard 24-month re-test window.
Yes. IGF-1 LR3 is listed as a nasal spray solution (0.1 mg, 1 mg), filled in 10 mL or 20 mL bottles, with an MOQ of 10 bottles per content and fill. It is dispatched within the United States from US inventory; send an inquiry for current availability.
Send any vial from your order to an independent laboratory of your choice. If the report shows the product does not meet the specification on its COA — purity below the stated minimum, or an identity that does not match — share the report with our sales team and we refund that product in full.